The RheumNow Week in Review - 6 October 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. In this week's report, Dr.
Patterns of Biologic Use During Autoimmune Pregnancy
While it is highly desirable to avoid medications during conception and pregnancy, statistics show that >90% of women take at least one drug during pregnancy and nearly half will take 3 or more medications during pregnancy.
29 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses regulatory actions by NICE and FDA, higher death rates in RA and psoriasis, increased risk of RA with Asthma, rising numbers for OA, RA, and STDs.
22 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.
Rituximab Efficacy in IgG4 Related Disease
PLOS reports greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD).
15 September 2017 The RheumNow Week in Review
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com. This week's report discusses metabolic syndrome in lupus, bisphosphonate holidays, vasculitis and vascular inflammation, Vaccination and the repeated wonders of Vitamin D.
Shingles Vaccine Studies in A&R
The current issue of Arthritis & Rheumatology features an editorial and two novel articles on the herpes zoster vaccine.
The RheumNow Week in Review – 18 August 2017
The RheumNow Week in Review discusses the past week's news, journal articles and highlights from RheumNow.com.
The RheumNow Week in Review – 4 August 2017
Dr. Jack Cush reviews new FDA decisions on sirukumab and tofacitinib as well as other news items from the past week on RheumNow.com.
The RheumNow Week in Review – 28 July 2017
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com:
The RheumNow Week in Review – 21 July 2017
Dr. Jack Cush reviews the news from the past week on RheumNow.com:
Forced, Rational or Glitch-Ridden Prescribing Practices
A recent analysis of 3 groups of treatment-naïve, early rheumatoid arthritis (ERA) patients looked at the factors that influenced the choice of therapy.
Social
To truly address adherence, you need to understand what is impairing it, and tailor an approach to overcome those barriers.
Great to see this articulated in EULAR recommendations re: non-adherence - a big factor in our therapeutic outcomes!
EULAR projects #EULAR2020 @RheumNow https://t.co/0pazcDFTuV
David Liew @drdavidliew ( View Tweet )
5 years 3 months ago
Is there subclinical GCA in PMR pts?
50 consecutive PMR pts had vascular USS. 27/50 had GCA vascular uptake, of which 10 had no GCA symptoms at all.
Is PMR sometimes just the tip of the GCA iceberg? Do the aSx USS+ pts get GCA Sx eventually?
Bonn SAT0254 #EULAR2020 @RheumNow https://t.co/UmsixY29Qh
David Liew @drdavidliew ( View Tweet )
5 years 3 months ago
GCA and cancer: it's been hard to tease apart, lots of cofounders. We've needed large cohorts with comparators & detail.
Large Israeli database says there are links
(EMR/claims/prescribing combined, n = 4.4m w validated incident GCA set). If so, why?
OP0143 #EULAR2020 @RheumNow https://t.co/kSPGnxNjah
David Liew @drdavidliew ( View Tweet )
5 years 3 months ago
#EULAR2020 Prof. T Domer: baricitinib show promise in phase II trial for SLE: Microarray analysis noted reduction in IFN signature; however, the reduction did not correlate w/SLEDAI-2K or SRI4 clinical response @RheumNow https://t.co/cW4egzSnAs
k dao @KDAO2011 ( View Tweet )
5 years 3 months ago
#EULAR2020 Most innovative! Vaccination with IFNa-kinoid to induce anti-IFNa antibodies to treat SLE (results of phase IIb trial). https://t.co/rM0z23ieQW @RheumNow https://t.co/OYMdDZl6sb
k dao @KDAO2011 ( View Tweet )
5 years 3 months ago
#EULAR2020 Dr. Kimme Hyrich reviews the EULAR #COVID19 Registry "Most individuals with rheumatic diseases receiving immunosuppressive therapies recover from COVID19" @rheumnow https://t.co/EdVLUMyHhF
k dao @KDAO2011 ( View Tweet )
5 years 3 months ago
#EULAR2020 panel on #COVID19 spec. situatns:
1. German regtry: very few preg rheum pts w/CV19; cases mild.
2. No info how CV19 affects APS
3. Very few ped rheum cases of CV19- cases mild; outcomes sim to gen peds pop
4. Most rheum pts w/CV19 good prognosis @rheumnow https://t.co/LQVdzJKCgu
k dao @KDAO2011 ( View Tweet )
5 years 3 months ago
#eular2020 #op0302 Ianalumab (VAY736) dual action BAFFreceptor inhibitor/B cell depletion meets primary end point in p2b for pSS: EESDAI⬇️1.92 pts over PBO at wk24. Dis not meet 2ry endpoint ESSPRI&FACIT-F. Good side effect profile w/mild inj site reactions mostly @RheumNow https://t.co/9qsfUNho9h
Olga Petryna @DrPetryna ( View Tweet )
5 years 3 months ago
New #therapeutic strategies in #SLE management
#EULAR2020 https://t.co/dhvTKd4EGB
dr hanady manasfi @hanadymanasfi ( View Tweet )
5 years 3 months ago
Our study shows that HCQ retinopathy virtually never occurs in first 5 yrs, SLE has more risk than other diseases such as RA and chloroquine has a far higher risk of retinal toxicity OP0333 #EULAR2020 @RheumNow @CRASCRRheum @earlyarthritis https://t.co/ZzRy3po4yw
Janet Pope @Janetbirdope ( View Tweet )
5 years 3 months ago
